• About us
• Contact

Advertisement

Organisation › Details

SystImmune Inc.

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies. Systimmune Inc., is a wholly owned and funded subsidiary of a Chinese pharmaceutical company. We are also seeking partners interested in working together to develop, commercialize, and bring our novel therapeutics to patients around the world. SystImmune Inc., has established three major technology platforms for the discovery and development of novel bio-therapeutics: 1. Antibody discovery: identification of monoclonal antibodies with unique characteristics through screening of thousands of target-specific IgG producing B cells using novel miniaturized immuno-assays 2. Bi-specific and multi-specific antibody engineering platforms 3. Process development platforms to manufacture our bio-therapeutics *

 

	Start	2014-01-01 established
	Group	Biokin (Group)
	Industry	therapeutic antibody
	Industry 2	antibody-drug conjugate (ADC)
	Street	15318 NE 95th Street
	City	98052 Redmond, WA
	Tel	+1-425-453-6841
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		�About Section� taken from web site of organisation on 19.05.
		Record changed: 2024-01-20

Advertisement

More documents for Biokin (Group)

• [1] Merck KGaA. (5/16/17). "Press Release: Merck’s CHOZN Expression System Selected for Bi-specific Antibody Development by SystImmune". Darmstadt....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.